First Exposure

Guaifenesin

Information last updated: May 2023 

The baseline risk of major birth defects in Canada is 3-5%. This means that 3-5 out of 100 babies born in the general population in Canada will be born with a major birth defect. There are also baseline risks for miscarriages (15-25 out of 100 pregnancies), prematurity and other outcomes. The information provided will summarize if taking this drug is likely to change these risks. 

Summary: Approximately 1000 pregnancies with exposure to guaifenesin were included in published studies. Based on these studies it is not expected that taking guaifenesin during pregnancy will cause more babies to be born with birth defects than in the general population. 

This information about guaifenesin is of a general nature and about medical use and does not replace the medical care and advice of your healthcare provider. For questions on dose, timing, side effects, interactions, etc., please consult your healthcare provider. Additionally, please read the patient insert provided with your medication. 

Although participants in the studies referenced below may have used guaifenesin in various combinations, the studies usually do not provide detailed information on drug combinations. This makes it challenging to comment on the safety of using this medication in combination with others during pregnancy or lactation.